Rumiko Shimazawa, Masayuki Ikeda. Potential adverse events in Japanese women who received tozinameran (BNT162b2, Pfizer-BioNTech). Journal of Pharmaceutical Policy and Practice. 2021. 14. 1. 46-46
Rumiko Shimazawa, Masayuki Ikeda. Approvals of type 2 diabetes drugs tested in cardiovascular outcome trials: A tripartite comparison. British Journal of Clinical Pharmacology. 2021. 87. 10. 3938-3948
Rumiko Shimazawa, Masayuki Ikeda. Regulatory perspectives on next-generation sequencing and complementary diagnostics in Japan. Expert review of molecular diagnostics. 2020. 20. 6. 601-610
朝倉 崇徳, 池田 正行, 中村 朗, 小寺 聡. ESBL産生EnterobacteriaceaeのUTIsに対する非カルバペネム系抗菌薬を用いた経験的治療の効果(Efficacy of empirical therapy with non-carbapenems for UTIs with ESBL-producing Enterobacteriaceae). 日本内科学会雑誌. 2015. 104. Suppl. 279-279
Draft Guidance for Industry and Food and Drug Administration Staff : In Vitro Companion Diagnostic Devices Draft Guidance. 2012. 43. 6. 514-519
Reflection Paper on Methodological Issues Associated with Pharmacogenomic Biomarkers in Relation to Clinical Development and Patient Selection : Draft (2). 2012. 43. 12. 1097-1105
EMAヒト用医薬品委員会, 嶋澤 るみ子, 池田 正行. Reflection Paper on Methodological Issues Associated with Pharmacogenomic Biomarkers in Relation to Clinical Development and Patient Selection : Draft (1). 医薬品医療機器レギュラトリーサイエンス. 2012. 43. 11. 1010-1016
Companion and Complementary Diagnostics From Biomarker Discovery to Clinical Implementation
Elsevier 2019
Companion Diagnostics (CDx) in Precision Medicine
Jenny Stanford Publishing 2019
Professional career (1):
医学博士 (東京医科歯科大学)
Association Membership(s) (4):
JAPAN PRIMARY CARE ASSOCIATION
, JAPANESE SOCIETY OF NEUROLOGY
, THE JAPANESE SOCIETY OF INTERNAL MEDICINE
, THE JAPANESE ASSOCIATION OF PHARMACEUTICAL MEDICINE